Suppr超能文献

中国医药创新政策的定量评估:基于 PMC-Index 模型。

Quantitative evaluation of the medicine innovation policy in China: based on the PMC-Index model.

机构信息

Shanghai International College of Intellectual Property, Tongji University, Shanghai, China.

出版信息

Front Public Health. 2024 May 16;12:1403320. doi: 10.3389/fpubh.2024.1403320. eCollection 2024.

Abstract

INTRODUCTION

Medicine innovation is crucial in promoting the sustainable development of medicine undertakings, which has significant economic and social benefits. China is the main force in global medicine consumption, with a huge demand for innovative medicines. Thus, the Chinese government releases a series of policies aimed at providing scientific and reasonable guidance for medicine innovation. However, there is inadequate quantitative evaluation and comparison of various medicine innovation policies in the existing studies.

METHODS

This paper adopts the approach of text mining and the Policy Modeling Consistency Index (PMC-Index) model to construct an evaluation system and then quantitatively evaluates and compares the traditional Chinese medicine innovation policies (TCMIPs), the biological medicine innovation policies (BMIPs), and the multiple medicine innovation policies (MMIPs) in China.

RESULTS

The results indicate that: (1) The three types of drug innovation policies have similarities in content and goal through comparative analysis of high-frequency words, while they also have their own characteristics. (2) The average PMC-Index of 29 TCMIPs is 5.77, which has the highest policy bad rate (21%); the average PMC-Index of 12 BMIPs is 6.21, which has the highest policy good rate (92%); moreover, the average PMC-Index of 35 MMIPs is 6.06, which has the highest policy excellence rate (26%). (3) The BMIPs, MMIPs, and TCMIPs have similar scores on policy object, policy orientation, policy timeliness, policy evaluation, and policy accessibility, while they differ significantly mainly on policy nature, incentive method, policy function, policy issuing agency, and policy instrument.

DISCUSSION

This study contributes to a comprehensive understanding of medicine innovation policies in China, in order to provide theoretical support for future policy formulation and optimization in the medicine industry. Moreover, we expand the application scenarios of policy diffusion theory.

摘要

简介

医学创新对于推动医学事业可持续发展具有重要意义,能够产生显著的经济和社会效益。中国是全球医药消费的主要力量,对创新药物有着巨大的需求。因此,中国政府发布了一系列政策,旨在为医学创新提供科学合理的指导。然而,现有研究中对各种医学创新政策的定量评估和比较还不够充分。

方法

本文采用文本挖掘和政策建模一致性指数(PMC-Index)模型构建评价体系,对中国的中药创新政策(TCMIPs)、生物药创新政策(BMIPs)和多类药物创新政策(MMIPs)进行定量评价和比较。

结果

研究结果表明:(1)通过高频词对比分析,三种类型的药物创新政策在内容和目标上具有相似性,但也各有特点。(2)29 项 TCMIP 的平均 PMC-Index 为 5.77,政策不良率最高(21%);12 项 BMIP 的平均 PMC-Index 为 6.21,政策优良率最高(92%);35 项 MMIP 的平均 PMC-Index 为 6.06,政策卓越率最高(26%)。(3)BMIPs、MMIPs 和 TCMIPs 在政策对象、政策导向、政策时效性、政策评价和政策可及性方面的得分较为接近,而在政策性质、激励方式、政策功能、政策制定机构和政策工具等方面差异较大。

讨论

本研究有助于全面了解中国的医学创新政策,为未来医药行业的政策制定和优化提供理论支持。此外,我们拓展了政策扩散理论的应用场景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e0c9/11137217/f707658bf74a/fpubh-12-1403320-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验